Agnes Shanley

Single-use equipment, analytics, and automation may add complexity, but they are reducing scale-up costs and timelines.

Joerg Ahlgrimm has left Lonza and is now leading The Discovery Labs’ mission to establish a powerhouse for cell and gene therapy development and manufacturing in the Philadelphia area.

Tufts research suggests costs to launch a new drug have doubled since 2003, but some question conclusions.